| Literature DB >> 35187057 |
Wenhui Wang1,2, Haiyan Liang2, Fang Zhao2, Huan Yu2, Chunhong Rong2, Weiwei Feng2,3, Qingyun Chen2, Yanjun Yang2, Qian Li2, Dingqing Feng2, Yuxiao Dong2,3, Ming Xue1,2, Jing Liang2, Bin Ling1,2,3.
Abstract
OBJECTIVE: To report a novel multi-port containment (NMC) system for laparoscopic power morcellation to prevent tumoral spread and to evaluate its safety, validity, and feasibility.Entities:
Keywords: containment system; laparoscopic myomectomy; power morcellation; uterine leiomyoma; uterine sarcoma
Year: 2022 PMID: 35187057 PMCID: PMC8850355 DOI: 10.3389/fsurg.2022.803950
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Study design.
Figure 2Main components of the novel multi-port containment (NMC) system. (A) The main components of the NMC system include the detachable peripheral trocar and the retrieval bag. (B) Detachable peripheral trocar (trocar base and trocar sheath). (C) Hard sheath on the bag and sealing cap. (D,E) Transposing sealing caps and trocar bases by threaded structures.
Figure 3Placement and extraction of the novel multi-port containment (NMC) system. (A) The bag is placed into the abdominal cavity through the right lower 20-mm introduction sheath. (B) The myoma is resected into the bag via its large opening. (C) The sealing caps on the hard sheaths are unscrewed and replaced with trocar bases. (D) The abdominal cavity is de-sufflated, and simultaneously, a pseudo-pneumoperitoneum is established by inflating the bag via the umbilical trocar. Thereafter, power morcellation is performed. (E) After morcellation, the trocar bases are unscrewed and replaced with the corresponding sealing caps. (F) The bag is removed through the introduction sheath. (G) Tissue and fluid remnants after morcellation in the NMC system. (H) 1,000-mL methylene blue solution is used to identify eventual system integrity.
Patient characteristics before and after propensity score matching.
|
| ||||||
|---|---|---|---|---|---|---|
|
|
| |||||
|
|
|
| ||||
| Age, mean (SD), y | 39.2 (6.4) | 39.2 (7.0) | 0.993 | 39.2 (7.0) | 38.7 (6.6) | 0.428 |
| BMI | 0.134 | 0.698 | ||||
| <19 | 17 (8.8) | 141 (8.0) | 17 (8.8) | 21 (10.9) | ||
| 19–24 | 117 (60.6) | 946 (54.0) | 117 (60.6) | 119 (61.7) | ||
| >24 | 59 (30.6) | 666 (38.0) | 59 (30.6) | 53 (27.5) | ||
| Gravidity, mean (SD) | 1.4 (1.4) | 1.8 (1.5) | <0.001 | 1.4 (1.4) | 1.6 (1.5) | 0.292 |
| Parity, mean (SD) | 0.6 (0.6) | 0.7 (0.7) | 0.034 | 0.6 (0.6) | 0.7 (0.6) | 0.654 |
| ASA score | 0.060 | 0.335 | ||||
| 1 | 161 (83.4) | 1,555 (88.7) | 161 (83.4) | 158 (81.9) | ||
| 2 | 32 (16.6) | 190 (10.8) | 32 (16.6) | 35 (18.1) | ||
| ≥3 | 0 (0) | 8 (0.5) | 0 | 0 | ||
| Diabetes | 0.099 | 1.000 | ||||
| Yes | 4 (2.1) | 84 (4.5) | 4 (2.1) | 3 (1.6) | ||
| No | 189 (97.9) | 1,669 (95.2) | 189 (97.9) | 190 (98.4) | ||
| Hypertension | 1.000 | 0.724 | ||||
| Yes | 3 (1.6) | 31 (1.8) | 3 (1.6) | 5 (2.6) | ||
| No | 190 (98.4) | 1,722 (98.2) | 190 (98.4) | 188 (97.4) | ||
| Hemoglobin level | 0.630 | 0.554 | ||||
| Normal | 169 (87.6) | 1,560 (89.0) | 169 (87.6) | 164 (85.0) | ||
| Abnormal | 24 (12.4) | 193 (11.0) | 24 (12.4) | 29 (15.0) | ||
| Major indications | 0.006 | 0.555 | ||||
| Menorrhagia | 675 (38.5) | 675 (38.5) | 88 (45.6) | 100 (51.8) | ||
| Intestinal and urinary tract disorders | 174 (9.9) | 174 (9.9) | 30 (15.5) | 21 (10.9) | ||
| Abdominal distention or pain | 114 (6.5) | 114 (6.5) | 13 (6.7) | 13 (6.7) | ||
| Fertility requirements | 666 (38.0) | 666 (38.0) | 54 (28.0) | 54 (28.0) | ||
| Others | 124 (7.1) | 124 (7.1) | 8 (4.1) | 5 (2.6) | ||
| History of abdominal/pelvic surgery | 0.376 | 0.498 | ||||
| No | 135 (69.9) | 1,169 (66.7) | 135 (69.9) | 142 (73.6) | ||
| Yes | 58 (30.1) | 584 (33.3) | 58 (30.1) | 51 (26.4) | ||
| Myomectomy | 8 | 75 | 8 | 7 | ||
| Cesarean section | 43 | 384 | 43 | 37 | ||
| Others | 14 | 178 | 14 | 12 | ||
| The average diameter of the largest tumor, mean (SD), cm | 7 (1.9) | 6.7 (2.1) | 0.001 | 7 (1.9) | 6.8 (2.0) | 0.147 |
| Location of the tumor | 0.590 | 1.000 | ||||
| Uterus | 176 (91.2) | 1,626 (92.8) | 176 (91.2) | 176 (91.2) | ||
| Cervical or uterus ligaments | 17 (8.8) | 123 (7.0) | 17 (8.8) | 17 (8.8) | ||
| Others | 0 (0) | 4 (0.2) | 0 (0) | 0 (0) | ||
| Number of the tumor | 2.7 (2.5) | 2.5 (2.2) | 0.521 | 2.7 (2.5) | 2.8 (2.5) | 0.618 |
BMI, body mass index; Normal hemoglobin level is ≥ 110 g/L.
Perioperative outcomes of the two groups.
|
| ||||||
|---|---|---|---|---|---|---|
|
|
| |||||
|
|
|
| ||||
| Leakage | 0 | – | – | 0 | – | – |
| Intra-op. complications | 0 | 4 | – | 0 | 0 | – |
| Post-op. complications | 9 (4.7) | 99 (5.6) | 0.625 | 9 (4.7) | 10 (5.1) | 1.000 |
| Total operative time, mean (SD), min | 119.9 (46.4) | 116.6 (46.7) | 0.349 | 119.9 (46.4) | 120.2 (44.2) | 0.953 |
| Estimated blood loss, mean (SD), ml | 73.7 (102.6) | 66.2 (91.8) | 0.271 | 73.7 (102.7) | 65.7 (76.2) | 0.621 |
| Postoperative hospitalization duration, | 3.8 (1.3) | 3.6 (1.3) | 0.004 | 3.8 (1.3) | 4.0 (1.4) | 0.442 |
Peri-operation complications of the two groups.
|
| ||||||
|---|---|---|---|---|---|---|
|
|
| |||||
|
|
|
|
|
|
| |
| Intra-op. complications | – | – | ||||
| Post-op. complications | 0.625 | 1.000 | ||||
EBL, estimated blood loss; AWV, abdominal wall vascular.
Initial pathology types of the two groups.
|
|
|
| ||
|---|---|---|---|---|
| Initial pathological types | UL | 143 (74.1) | 1,259 (71.8) | 0.414 |
| Special types of UL | 49 (25.4) | 489 (27.9) | ||
| Uterine sarcoma | 1 (0.5) | 5 (0.3) |
UL, uterine leiomyoma.
Special types uterine leiomyoma including atypical leiomyomas, cell-rich leiomyomas, and leiomyomas with uncertain malignant potential, et al.
Patients with unexpected uterine sarcoma during laparoscopic surgeries for uterine leiomyoma.
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|
| Study group | 1 | 26 | ULMS | Ia | LH + BS | No | 24 | Survival |
| Control group | 1 | 32 | ULMS | Ia | LH + BSO | No | 62 | Survival |
| 2 | 36 | ESS | Ib | LH + BSO | Yes (2 months) | 25 | Die | |
| 3 | 41 | ULMS | Ia | LH + BSO | No | 72 | Survival | |
| 4 | 41 | ULMS | Ia | LH + BSO | Yes (5 months) | 73 | Survival | |
| 5 | 43 | ULMS | Ia | LH + BSO | Yes (6 months) | 71 | Survival |
FIGO, The International Federation of Gynecology and Obstetrics; ULMS, uterine leiomyosarcoma; ESS, endometrial stromal sarcoma; LH + BS, laparoscopic hysterectomy; bilateral salpingectomy; LH + BSO, laparoscopic hysterectomy, bilateral salpingo-oophorectomy.
Power morcellation-related reoperation of benign pathologies in the control group.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Parasitic | 1 | 20 | Leiomyoma | 31 | Pelvic leiomyoma |
| 2 | 35 | Leiomyoma | 33 | Pelvic leiomyoma | |
| 3 | 41 | Leiomyoma | 66 | Pelvic leiomyoma | |
| 4 | 37 | Cell-rich leiomyoma | 54 | Trocar site of the previous LM | |
| DPL | 5 | 33 | STUMP | 36 | Peritoneum, Omentum, |
| 6 | 36 | Leiomyoma | 73 | Peritoneum, Omentum, Mesocolon |
LM, laparoscopic myomectomy; DPL, disseminated peritoneal leiomyomatosis.